Cytomel

CytoMed Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel cell-based immunotherapies for the treatment of cancers. Based in Singapore, the company leverages its proprietary platform technologies to create off-the-shelf allogeneic cell therapies, primarily utilizing gamma delta T cells and natural killer (NK) cells. Their lead candidate, CTM-N2D, is a chimeric antigen receptor (CAR)-modified gamma delta T cell therapy targeting NKG2D ligands on various solid tumors and hematological malignancies. CytoMed aims to address the limitations of current CAR-T therapies by providing more accessible and cost-effective treatments through its induced pluripotent stem cell (iPSC) technology. The company is currently conducting Phase 1 clinical trials and is listed on the NASDAQ exchange.